A long-term safety study of lumateperone in patients with schizophrenia

Trial Profile

A long-term safety study of lumateperone in patients with schizophrenia

Planning
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 04 May 2017 New trial record
    • 01 May 2017 According to an Intra-Cellular Therapies media release, based on the responses regarding the nonclinical findings, US FDA may place hold on this trial. This trial will support an NDA approval for schizophrenia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top